NLRP3 and gout: Given that COVID-19 (46–48), other viral or bacterial infections (49–51), and conditions such as rheumatoid arthritis and gout (52, 53) can also lead to NLRP3 inflammasome activation and induce excessive immune responses, PP may also exert inhibitory effects on inflammation induced by these diseases.